Kuros Biosciences AG (KURN) - Financial and Strategic SWOT Analysis Review

Kuros Biosciences AG (KURN) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH81908FSA
  • |
  • Pages: 46
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Kuros Biosciences AG (KURN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and as surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company's lead sealant product is Neuroseal (KUR-023) developed as an adjunct to suturing for sealing of the dura after cranial surgery. Kuros Biosciences is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG Key Recent Developments

Sep 05,2018: Kuros Biosciences announces results for first half 2018

Aug 23,2018: Kuros Biosciences names Pascal Longlade as chief medical officer

May 31,2018: Kuros Biosciences to Propose Appointment of New Board Members at AGM

Apr 30,2018: Kuros Biosciences Reports Full-Year 2017 Results

Mar 12,2018: Kuros Biosciences obtains European patent covering osteoinductive materials

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Kuros Biosciences AG-Key Facts 6

Kuros Biosciences AG-Key Employees 7

Kuros Biosciences AG-Key Employee Biographies 8

Kuros Biosciences AG-Major Products and Services 9

Kuros Biosciences AG-History 10

Kuros Biosciences AG-Company Statement 13

Kuros Biosciences AG-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2-Company Analysis 15

Company Overview 15

Kuros Biosciences AG-Business Description 16

R&D Overview 16

Kuros Biosciences AG-SWOT Analysis 17

SWOT Analysis-Overview 17

Kuros Biosciences AG-Strengths 17

Kuros Biosciences AG-Weaknesses 18

Kuros Biosciences AG-Opportunities 19

Kuros Biosciences AG-Threats 20

Kuros Biosciences AG-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's, Lifesciences Financial Deals and Alliances 28

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Kuros Biosciences AG, Recent Deals Summary 30

Section 5-Company's Recent Developments 31

May 31, 2018: Kuros Biosciences to Propose Appointment of New Board Members at AGM 31

Apr 30, 2018: Kuros Biosciences Reports Full-Year 2017 Results 32

Apr 30, 2018: Kuros Biosciences Reports Full-Year 2017 Results 33

Mar 12, 2018: Kuros Biosciences obtains European patent covering osteoinductive materials 34

Dec 14, 2017: Kuros Biosciences Announces Management Succession 35

Nov 28, 2017: Kuros Biosciences' Chief Medical Officer to Retire 36

Nov 16, 2017: Kuros announces management changes 37

Sep 26, 2017: Kuros Biosciences Reports Financial Results for First Half-Year of 2017 38

Apr 28, 2017: Kuros Biosciences Proposes Election of Four New Board Members 39

Apr 26, 2017: Kuros Biosciences Reports Financial Results for 2016 40

Section 6-Appendix 42

Methodology 42

Ratio Definitions 42

About GlobalData 46

Contact Us 46

Disclaimer 46

List of Figures

Kuros Biosciences AG, Performance Chart (2012-2016) 25

Kuros Biosciences AG, Ratio Charts 27

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

List of Tables

Kuros Biosciences AG, Key Facts 6

Kuros Biosciences AG, Key Employees 7

Kuros Biosciences AG, Key Employee Biographies 8

Kuros Biosciences AG, Major Products and Services 9

Kuros Biosciences AG, History 10

Kuros Biosciences AG, Subsidiaries 14

Kuros Biosciences AG, Key Competitors 21

Kuros Biosciences AG, Ratios based on current share price 22

Kuros Biosciences AG, Annual Ratios 23

Kuros Biosciences AG, Annual Ratios (Cont...1) 24

Kuros Biosciences AG, Interim Ratios 26

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Kuros Biosciences AG, Recent Deals Summary 30

Currency Codes 42

Capital Market Ratios 42

Equity Ratios 43

Profitability Ratios 43

Cost Ratios 44

Liquidity Ratios 44

Leverage Ratios 45

Efficiency Ratios 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

SciBase AB

IsoTis SA

Geistlich Pharma AG

Elanix Biotechnologies AG

Basilea Pharmaceutica Ltd

Kuros Biosciences AG, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8750
Site License
USD 250 INR 17500
Corporate User License
USD 375 INR 26250

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com